Concord Drugs Peer Comparison

Snapshot Summary

Concord Drugs Ltd. significantly underperforms in key financial metrics compared to its peers in the Pharmaceuticals & Drugs sector, showcasing low revenue growth, poor profitability, and high valuation ratios. It is a weak investment choice relative to its competitors, which display stronger fundamentals and growth trajectories.

• Concord Drugs Ltd. has negative revenue growth and the lowest ROE among peers.
• High PE ratio indicates overvaluation relative to earnings, alongside low margins.
• Strong competitors like Sun Pharmaceutical and Dr. Reddy's exhibit robust growth and profitability.

• Sun Pharmaceutical Industries Ltd.: Highest profitability with a strong ROE (16.13) and consistent revenue growth.
• Dr. Reddy's Laboratories Ltd.: Strong EPS growth and low PE ratio indicate excellent value with high profitability.
• Cipla Ltd.: Strong revenue growth and profitability metrics make it an attractive choice.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
Concord Drugs Ltd.	₹67.01	₹67.01Cr	156.93	1.45%	4.99%	0.52
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Concord Drugs Peer Comparison

Snapshot Summary